docetaxel + sepantronium bromide

Docetaxel + sepantronium bromide is a combination therapy consisting of docetaxel, a taxane-based chemotherapeutic agent, and sepantronium bromide (YM155), a small molecule inhibitor of survivin. Docetaxel works by disrupting microtubule function, which is essential for cell division, while sepantronium bromide suppresses survivin expression, a protein that inhibits apoptosis and is overexpressed in many cancer types. The combination has demonstrated synergistic antitumor effects in various cancer models, including ovarian cancer, triple-negative breast cancer, and melanoma. YM155 enhances docetaxel efficacy by downregulating survivin expression, particularly at the G2/M phase of the cell cycle, leading to increased apoptosis compared to either agent alone. Clinical trials have investigated this combination for treating stage III (unresectable) or stage IV melanoma.

Other names

Taxotere + YM155Taxotere + sepantronium bromidedocetaxel + YM155